FYI - Acadia presented at GS healthcare conference overnight.
Whilst most of their half hour slot was on Nuplazid, the last couple of minutes were discussing the Retts syndrome compound.
Gives some really nice context to the deal from an Acadia business development perspective. Its the kind of compound that aligns to where they want to head with the business.
Also hints that there will be more deals such as the trof one in the near future. - read into that what you will - however if this is the sort of compound they want to go after - boy how about 2591.
You can listen in here ->
https://event.webcasts.com/starthere.jsp?ei=1247214&tp_key=469ab66e49
Goldman Sachs Healthcare Conference
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.87 |
Change
0.320(1.56%) |
Mkt cap ! $2.667B | |||
| Open | High | Low | Value | Volume |
| $20.86 | $21.29 | $20.84 | $3.796M | 180.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $20.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.87 | 844 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |